Cystatin C Human ELISA

Summary

Cystatin C is a non-glycosilated basic single-chain protein consisting of 120 amino acids with a molecular weight of 13.36 kDa and is characterized by two disulfide bonds in the carboxy-terminal region. It belongs to the cystatins superfamilly which inactivates lysosomal cysteine proteinases, e.g. cathepsin B, H,.K, L and S. Imbalance between Cystatin C and cysteine proteinases is associated with inflammation, renal failure, cancer, Alzheimer's di­sease, multiple sclerosis and hereditary Cystatin C amyloid angiopathy. Its increased level has been found in patients with autoimune diseases, with colorectal tumors and in patients on dyalisis. Serum Cystatin C seems to be better marker of glomerular filtration rate than creatinine. On the other hand, low concentration of Cystatin C presents a risk factor for secondary cardiovascular events.

Features

• European Union: for in vitro diagnostic use

Rest of the world: for research use only!

• The total assay time is less than 2 hours
• The kit measures total cystatin C in serum, plasma (EDTA, citrate, heparin), urine and cerebrospinal fluid
• Assay format is 96 wells
• Quality Controls are human serum or human urine native protein based. No animal sera are used
• Standard is purified native protein based
• Components of the kit are provided ready to use or concentrated
• Convenient for automatization

Research topic

Renal disease

Assay format

Sandwich ELISA, HRP-labelled antibody

Applications

Cerebrospinal fluid, Plasma-Citrate, Plasma-EDTA, Plasma-Heparin, Serum, Urine

Sample requirements

10 µl/well

Storage/Shipping

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration range

200 – 10 000 ng/ml

Limit of detection

0.25 ng/ml

Intra-assay (Within-Run, n=8)

CV = 2.5 %

Inter-assay (Run-to-Run, n=5)

CV = 6.9 %

Spiking Recovery

95 %

Dilution Linearity

97.8 %

Cross-Reactivity

References to this product

• Adanir T, Aksun M, Cirit M, Alkan Tasli F, Sahin O, Kestelli M, Aydin Kantaroglu T, Koseoglu M, Sencan A, Karahan N. The renal effect of replacement fluids in controlled severe hemorrhagic shock: an experimental study. Ulus Travma Acil Cerrahi Derg. 2009 Sep;15 (5):423-32
• Albayrak S, Ordu S, Ozhan H, Yazici M, Aydin M, Alemdar R, Kaya A. Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function. Blood Press. 2009 Sep;18 (4):187-91
• Barrientos LG, Rollin PE. Release of cellular proteases into the acidic extracellular milieu exacerbates Ebola virus-induced cell damage. Virology . Sep 15 (2006)
• Bayram A,Esmaoglu A, Akin A,Baskol G, Aksu R, Bicer C, Demirtas A, Mutluay R, Boyaci A. The effects of intraoperative infusion of dexmedetomidine on early renal function after percutaneous nephrolithotomy. Acta Anaesthesiologica Scandin. 2011; 55;:539–544
• Chung MY, Jun DW, Sung SA. Diagnostic value of cystatin C for predicting acute kidney injury in patients with liver cirrhosis. Korean J Hepatol. 2010 Sep;16 (3):301-7
• Esezobor CI, Iroha E, Oladipo O, Onifade E, Soriyan OO, Akinsulie AO, Temiye EO, Ezeaka C. Kidney function of HIV-infected children in Lagos, Nigeria: using Filler's serum cystatin C-based formula. J Int AIDS Soc. 2010;13:17
• Hilmi IA, Peng Z, Planinsic RM, Damian D, Dai F, Tyurina YY, Kagan VE, Kellum JA. N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. Nephrol Dial Transplant. 2010 Feb 22;
• Hossain MA, Emara M, El Moselhi H, Shoker A. Comparing measures of cystatin C in human sera by three methods. Am J Nephrol. 2009;29 (5):381-91
• Korolenko TA, Filatova TG, Cherkanova MS, Khalikova TA, Bravve IIu. [Cystatins: cysteine proteases regulation and disturbances in tumors and inflammation]. Biomed Khim. 2008 Mar-Apr;54 (2):210-7
• Koyner JL, Bennett MR, Worcester EM, Ma Q, Raman J, Jeevanandam V, Kasza KE, O'Connor MF, Konczal DJ, Trevino S, Devarajan P, Murray PT. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int. 2008 Oct;74 (8):1059-69
• Lapinski TW, Parfieniuk A, Rogalska-Plonska M, Czajkowska J, Flisiak R. Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected individuals: implications for renal function. Liver Int. 2009 Sep;29 (8):1158-61
• Liu X, Zeng B, Xu J. Alteration of cystatin C in cerebrospinal fluid of patients with sciatica revealed by a proteomical approach. Saudi Med J. 2005 Nov;26 (11):1699-704
• Liu XD, Zeng BF, Xu JG, Zhu HB, Xia QC. Proteomic analysis of the cerebrospinal fluid of patients with lumbar disk herniation. Proteomics . Feb;6(3):1019-28 (2006)
• Malamitsi-Puchner A, Briana DD, Kontara L, Boutsikou M, Baka S, Hassiakos D, Marmarinos A, Gourgiotis D. Serum cystatin C in pregnancies with normal and restricted fetal growth. Reprod Sci. 2007 Jan;14 (1):37-42
• Mareš J, Herzig R, Stejskal D, Vavroušková J, Hluštík P, Urbánek K, Vránová H, Zapletalová J, Pidrman V, Kaňovská P. Use of new markers in the diagnostics of neurodegenerative diseases. Scripa Medica (Brno). 79 (1): 59–68, February 2006;
• Mares J, Kanovsky P, Herzig R, Stejskal D, Vavrouskova J, Hlustik P, Vranova H, Burval S, Zapletalova J, Pidrman V, Obereigneru R, Suchy A, Vesely J, Podivinsky J, Urbanek K. New laboratory markers in diagnosis of alzheimer dementia. Neurol Res. 2009 Dec;31 (10):1056-9
• Mares J, Kanovsky P, Herzig R, Stejskal D, Vavrouskova J, Hlustik P, Vranova H, Burval S, Zapletalova J, Pidrman V, Obereigneru R, Suchy A, Vesely J, Podivinsky J, Urbanek K. The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases. Neurol Sci. 2009 Feb;30 (1):1-7
• Miele G, Seeger H, Marino D, Eberhard R, Heikenwalder M, Stoeck K, Basagni M, Knight R, Green A, Chianini F, Wuthrich RP, Hock C, Zerr I, Aguzzi A. Urinary alpha1-antichymotrypsin: a biomarker of prion infection. PLoS One. 2008;3 (12):e3870
• Nakae H, Igarashi T, Tajimi K, Noguchi A, Takahashi I, Tsuchida S, Takahashi T, Asanuma Y. A case report of pediatric fulminant hepatitis treated with plasma diafiltration. Ther Apher Dial. 2008 Aug;12 (4):329-32
• Pasa S, Bayramli G, Atasoy A, Karul A, Ertug S, Ozensoy Toz S. Evaluation of serum cystatin-C in dogs with visceral leishmaniasis. Vet Res Commun. 2009 Jan 13;
• Pasa S, Kilic N, Atasoy A, Derincegoz OO, Karul A. Serum Cystatin C Concentration as a Marker Acute Renal Dysfunctionin Critically Ill Dogs. J Anim Vet Advances. 2008, 7 (11): 1410-1412;
• Saito T, Urushihara M, Kotani Y, Kagami S, Kobori H. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci. 2009 Dec;338 (6):478-80
• Shaarawy M, Fathy SA, Mehany NL, Hindy OW. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. Clin Chem Lab Med. 2007;45 (11):1498-503
• Stejskal D, Vavrouskova J, Mares J, Urbanek K. Applications of new laboratory marker assays in neurological diagnoses - A pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub . Dec;149(2):265-6 (2005)
• Straface E, Matarrese P, Gambardella L, Vona R, Sgadari A, Silveri MC, Malorni W. Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: a pilot study. FEBS Lett . May 23;579(13):2759-66 (2005)
• Taleb S, Cancello R, Clement K, Lacasa D. Cathepsin S promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. Endocrinology . Oct;147(10):4950-9 (2006)
• Taleb S, Cancello R, Poitou C, Rouault C, Sellam P, Levy P, Bouillot JL, Coussieu C, Basdevant A, Guerre-Millo M, Lacasa D, Clement K. Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. J Clin Endocrinol Metab . Mar;91(3):1042-7 (2006)
• Taleb S, Lacasa D, Bastard JP, Poitou C, Cancello R, Pelloux V, Viguerie N, Benis A, Zucker JD, Bouillot JL, Coussieu C, Basdevant A, Langin D, Clement K. Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J . Sep;19(11):1540-2 (2005)
• Trenchevska O, Nedelkov D. Targeted quantitative mass spectrometric immunoassay for human protein variants. Proteome Sci. 2011;9 (1):19
• Tumminello FM, Flandina C, Crescimanno M, Leto G. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Biomed Pharmacother. 2008 Feb;62 (2):130-5
• von Eynatten M, Liu D, Hock C, Oikonomou D, Baumann M, Allolio B, Korosoglou G, Morcos M, Campean V, Amann K, Lutz J, Heemann U, Nawroth PP, Bierhaus A, Humpert PM. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes. 2009 Sep;58 (9):2093-9
• Woischnik M, Bauer A, Aboutaam R, Pamir A, Stanzel F, de Blic J, Griese M. Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis. Eur Respir J. 2008 Jun;31 (6):1197-204
• Yang X, Wang H, Wang Z, Dong M. Alteration and significance of serum cardiac troponin I and cystatin C in preeclampsia. Clin Chim Acta . Dec;374(1-2):168-9 (2006)
• Yang Y, Liu S, Qin Z, Cui Y, Qin Y, Bai S. Alteration of cystatin C levels in cerebrospinal fluid of patients with Guillain-Barre Syndrome by a proteomical approach. Mol Biol Rep. 2009 Apr;36 (4):677-82
• Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008 Jan 15;14 (2):470-7

References to summary

• Lindahl P., Abrahamson M., Bjork I.: Interaction of recombinant human cystatin C with the cysteine proteinases papain and actinidin. Biochem J 1992; 281: 49–55
• Ekiel I. and Abrahamson M.: Folding-related dimerization of human cystatin C. J Biol Chem 1996; 271: 1314–1321
• Ekiel I., Abrahamson M., Fulton D.B., Lindahl P., Storer A.C., Levadoux W., Lafrance M., Labelle S., Pomerleau Y., Groleau D., LeSauteur L., Gehring K.: NMR structural studies of human cystatin C dimmers and monomers. J Mol Biol 1997; 271: 266–277
• Tian S., Kusano E., Ohara T., Tabei K., Itoh Y., Kawai T., Asano Y.: Cystatin C measurement and its practical use in patients with various renal diseases. Clin Nephrol 1997; 48: 104–108
• Walker L.C.: Animal models of cerebral beta-amyloid angiopathy. Brain Res Rev 1997; 25: 70–84
• Lerner U.H., Johansson L., Ranjso M., Rosenquist J.B., Reinholt F.P., Grubb A.: Cystatin C, an inhibitor of bone resorption produced by osteoblasts. Acta Physiol Scand 1997; 161: 81–92
• Bokenkamp A., Domanetzki M., Zinck R., Schumann G., Byrd D., Brodehl J.: Cystatin C – a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998; 101: 875–881
• Shi G.P., Sukhova G.K., Grubb A., Ducharme A., Rhode L.H., Lee R.T., Ridker P.M., Libby P., Chapman H.A.: Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191–1197
• Risch L., Blumberg A., Huber A.: Rapid and accurate assessment of glomerular filtration rate in patients with renal transplants using serum cystatin C. Nephrol Dial Transplant 1999; 14: 1991–1996
• Le Bricon T., Thervet E., Benlakehal M., Bousquet B., Legendre C., Erlich D.: Changes in plasma cystatin C after renal transplantation and acute rejection in adults. Clin Chem 1999; 45: 2243–2249
• Cimerman N., Brguljan P.M., Krasovec M., Suskovic S., Kos J.: Twenty-four hour variations of cystatin C and total cysteine proteinase inhibitory activity in sera from healthy subjects. Clin Chim Acta 2000; 291: 89–95
• Stabuc B., Vrhovec L., Stabuc-Silih M., Cizej T.E.: Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 2000; 46: 193–197
• Mangge H., Liebmann P., Tanil H., Herrmann J., Wagner C., Gallistl S., Schauenstein K., Erwa W.: Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis. Clin Chim Acta 2000; 300: 195–202
• Takeuchi M., Fukuda Y., Nakano I., Katano Y., Hayakawa T.: Evaluation of serum cystatin C concentrations in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2001; 13: 951–955
• Bokenkamp A., Dieterich C., Dressler F., Muhlhaus K., Gembruch U., Bald R., Kirschstein M.: Fetal serum concentrations of cystatin C and beta2-microglobulin as predictors of postnatal kidney function. Am J Obstet Gynecol 2001; 185: 468–475
• Deng A., Irizarry M.C., Nitsch R.M., Growdon J.H., Rebeck G.W.: Elevation of cystatin C in susceptible neurons in Alzheimer's di­sease. Am J Pathol 2001; 159: 1061–1068
• Demirtas S., Bozbas A., Akbay A., Yavuz Y., Karaca L.: Diagnostics value of cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001; 311: 81–89
• Lindholt J.S., Erlandsen E.J., Henneberg E.W.: Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms. Br J Surg 2001; 88: 1472–1475
• Tan G.D., Lewis A.V., JamesT.J., Altmann P., Taylor R.P., Levy J.C.: Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 2002; 25: 2004–2009
• Mussap M., Dalla Vestra M., Fioretto P., Saller A., Varagnolo M., Nosadini R., Plebani M.: Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 61: 1453–1461
• Kazama J.J., Kutsuwada K., Ataka K., Maruyama H., Gejyo F.: Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron 2002; 91: 13–20
• Uchida K. and Gotoh A.: Measurement of cystatin-C and creatinine in urine. Clin Chim Acta 2002; 323: 121–128 Human Cystatin C ELISA (page 24 of 28) VERSION 33 160707 04
• Dharnidharka V.R., Kwon C., Stevens G.: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221–226
• Mares J., Stejskal D., Vavrouskova J., Urbanek K., Herzig R., Hlustik P.: Use of cystatin C determination in clinical diagnostics. Biomed Papers 2003; 147: 177–180
• Mojiminiyi O.A. and Abdella N.: Evaluation of cystatin C and beta-2 microglobulin as markers of renal function in patients with type 2 diabetes mellitus. J Diabetes Complications 2003; 17: 160–168
• Benussi L., Ghidoni R., Steinhoff T., Alberici A., Villa A., Mazzoli F., Nicosia F., Barbiero L., Broglio L., Feudatari E., Signorini S., Finckh U., Nitsch R.M., Binetti G.: Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol Dis 2003; 13: 15–21
• Perlemoine C., Beauvieux M.C., Rigalleau V., Baillet L., Barthes N., Derache P., Gin H.: Interest of cystatin C in screening diabetic patients for early impairment of renal function. Metabolism 2003; 52: 1258–1264
• Wiesli P., Schwegler B., Spinas G.A., Schmid C.: Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta 2003; 338: 87–90
• Watanabe S., Okura T., Liu J., Miyoshi K., Fukuoka T., Hiwada K., Higaki J.: Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 2003; 26: 895–899
• Mussap M. and Plebani M.: Biochemistry and Clinical Role of Human Cystatin C. Crit Rev Clin Lab Sci 2004; 41: 467–550
• Johnston N., Jernberg T., Lindahl B., Lindback J., Stridsberg M., Larsson A., Venge P., Wallentin L.: Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 2004; 37: 210–216
• Weiner D.E., Tighiouart H., Stark P.C., Amin M.G., MacLeod B., Griffith J.L., Salem D.N., Levevy A.S., Sarnak M.J.: Kidney disease as a risk factor for recurrent cardiovascular disease and mortatlity. Am J Kidney Dis 2004; 44: 198–206
• Jernberg T., Lindhal B., James S., Larsson A., Hansson L.O., Wallentin L.: Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004; 110: 2342–2348
• Koenig W., Twardella D., Brenner H., Rothenbacher D.: Plasma Concentrations of Cystatin C in Patients with Coronary Heart Disease and Risk for Secondary Cardiovascular Events: More Than Simply a Marker of Glomerular Filtration Rate. Clin Chem 2004
• Shlipak M.G., Sarnak MJ, Katz R, Fried L, Seliger S, Newman A, Siscovick D, Stehman-Breen C.: Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 2005; 45: 268–271
• Artunc F.H., Fischer I.U., Risler T., Erley C.M.: Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. Int J Cardiol 2005; 102: 173–178
• Luc G., Bard J.M., Lesueur C., Arveiler D., Evans A., Amouyel P., Ferrieres J., Juhan-Vague I., Fruchart J.C., Ducimetiere P.: Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis 2005
• Noto D., Cefalu A.B., Barbagallo C.M., Pace A., Rizzo M., Marino G., Caldarella R., Castello A., Pernice V., Notarbartolo A., Averna M.R.: Cystatin C levels are decreased in acute myocardial infarction; Effect of cystatin C G73A gene polymorphism on plasma levels. Int J Cardiol 2005; 101: 213–217
• Conti M., Zater M., Lallali K., Durrbach A., Moutereau S., Manivet P., Eschwege P., Loric S.: Absence of circadian variations in urine cystatin C allows its use on urinary samples. Clin Chem 2005; 51: 272–273
• Seliger S.L., Longstreth W.T. Jr., Kratz R., Manolio T., Fried L.F., Shlipak M., Stehman-Breen C.O., Newman A., Sarnak M., Gillen D.L., Bleyer A., Siscovick D.S.: Cystatin C and subclinical brain infarction. J Am Soc Nephrol. 2005; 16: 3721–3727
• Fried L.F., Kratz R., Sarnak M.J., Shlipak M.G., Chaves P.H., Jenny N.S., Stehman-Breen C., Gillen D., Bleyer A.J., Hirsch C., Siscovick D., Newman A.B.: Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005; 16: 3728–3735
• Shlipak M.G., Wassel Fyr C.L., Chertow G.M., Harris T.B., Kritchevsky S.B., Tylavsky F.A., Satterfield S., Cummings S.R., Newman A.B., Fried L.F.: Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006; 17: 254–261
• Kato T., Heike T., Okawa K., Haruyama M., Shiraishi K., Yoshimoto M., Nagato M., Shibata M., Kumada T., Yamanaka Y., Hatorri H., Nakahata T.: A neurosphere-derived factor, cystatin C, supports differentiation of ES cells into neural stem cells. Proc Natl Acad Sci U S A. 2006;103: 6019–6024 Human Cystatin C ELISA (page 25 of 28) VERSION 33 160707 04
• Conti M., Moutereau S., Zater M., Lallali K., Durrbach A., Manivet P., Eschwege P., Loric S.: Urinary cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med. 2006; 44: 288–291
• Macisaac R.J., Tsalamandris C., Thomas M.C., Premaratne E., Panagiotopoulos S., Smith T.J., Poon A., Jenkins M.A., Ratnaike S.I., Power D.A. Jerums G.: Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia. 2006; 49: 1686–1689
• Nakashima I., Fujihara K., Fujinoki M., Kawamura T., Nishimura T., Nakamura M., Itoyama Y.: Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Ann Neurol. 2006
• Fried L.F., Biggs M.L., Shlipak M.G., Seliger S., Kestenbaum B., Stehman-Breen C., Sarnak M., Siscovick D., Harris T., Cauley J., Newman A.B., Robbins J.: Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007; 18: 282–286

By research topic:

• Renal disease

By molecule:

• Cystatin C

Registration form